Drug Trial Radar · NCT02767804
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Last checked: Nov 20, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
290
Actual
Start
Jun 2016
Primary completion
Dec 30, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Xcovery Holdings, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.
Conditions
- Non-small Cell Lung Cancer
Interventions
X-396 (ensartinib)Drug
oral ALK inhibitor
crizotinibDrug
oral ALK inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: 36 months
Locations
72 sites in 20 countries. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida
University Cancer & Blood Center
Athens, Georgia
Washington University School of Medicine
St Louis, Missouri
Providence Portland Medical Center
Portland, Oregon
Sanatorio Parque S.A.
Rosario, Argentina
Chris O Brien Lifehouse
Camperdown, Australia
Border Medical Oncology Research Unit
Albury, New South Wales, Australia
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Catholic University of Louvain (UCL) - Site Mont Godinne
Yvoir, Belgium
Hospital Haroldo Juaçaba - Instituto do Cancêr do Ceará
Fortaleza, Brazil
Fundacao do ABC Faculdade de Medicina do ABC
São Paulo, Brazil
Instituto do Câncer do Estado de São Paulo
São Paulo, São Paulo, Brazil
Hospital de Câncer de Barretos - Fundação Pio XII
São Paulo, São Paulo, Brazil
Infirmière recherche Clinique, IUCPQ
Québec, Quebec, Canada
Peking University Cancer Hospital
Beijing, China
Zhejiang Cancer Hospital
Hangzhou, China
Anhui Provincial Hospital
Hefei, Anhui, China
Beijing Chao Yang Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Beijing Chest Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Guangdong General Hospital
Guangzhou, Guangdong, China
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Hunan Cancer Hospital
Changsha, Hu'nan, China
Union Hospital of Tongji Medical College of Huazhong Science and Techology University
Wuhan, Hubei, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Nanjing General Hospital
Nanjing, Jiangsu, China
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
Jilin Cancer Hospital
Changchun, Jilin, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Vítkovická Nemocnice , a.s.
Ostrava-Vitkovice, Czechia
Krajská zdravotní, a.s., Masarykova nemocnice
Ústí nad Labem, Czechia
CHRU Lille
Lille, France
Hopital Arnaud de Villeneuve
Montpellier, France
CHU de Rennes Hôpital Pontchaillou
Rennes, France
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.